Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Diroximel fumarate

First Posted Date: 2021-11-19

Last Posted Date: 2022-07-05

Lead Sponsor: Biogen

Target Recruit Count: 32

Registration Number: NCT05127564

Locations: 🇳🇿
Research Site, Christchurch, New Zealand

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C] BIIB122 ([14C] DNL151)

First Posted Date: 2021-11-15

Last Posted Date: 2021-12-07

Lead Sponsor: Biogen

Target Recruit Count: 7

Registration Number: NCT05119790

Locations: 🇺🇸
Pharmaron CPC, Baltimore, Maryland, United States

A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders

Not Applicable

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Device: Konectom NMD Application

First Posted Date: 2021-11-05

Last Posted Date: 2024-02-06

Lead Sponsor: Biogen

Target Recruit Count: 93

Registration Number: NCT05109637

Locations: 🇩🇪
LMU Klinikum Friedrich-Baur-Institute, Dept. of Neurology, Munich, Germany
🇩🇪
Research Site, Heidelberg, Germany

A Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue Damage

Completed

Conditions: Multiple Sclerosis (MS)

Interventions: Device: Konectom platform

First Posted Date: 2021-11-03

Last Posted Date: 2024-05-17

Lead Sponsor: Biogen

Target Recruit Count: 200

Registration Number: NCT05106465

Locations: 🇩🇪
Multiple Sclerosis Centre, Dresden, Germany

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

Terminated

Conditions: Alzheimers Disease

First Posted Date: 2021-10-27

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 29

Registration Number: NCT05097131

Locations: 🇺🇸
Research Site, Canton, Ohio, United States
🇺🇸
Imic, Inc., Palmetto Bay, Florida, United States
🇺🇸
Northwest Neurology, Chicago, Illinois, United States

and more 14 locations

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Phase 3

Recruiting

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: Diroximel fumarate

First Posted Date: 2021-10-19

Last Posted Date: 2024-08-26

Lead Sponsor: Biogen

Target Recruit Count: 100

Registration Number: NCT05083923

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Beijing Hospital, Beijing, Beijing, China
🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

and more 49 locations

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)

Phase 3

Active, not recruiting

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Nusinersen

First Posted Date: 2021-10-05

Last Posted Date: 2025-05-06

Lead Sponsor: Biogen

Target Recruit Count: 45

Registration Number: NCT05067790

Locations: 🇧🇷
Hospital das Clinicas - FMUSP, Sao Paulo, Brazil
🇩🇪
Charité - Campus Virchow-Klinikum, Berlin, Germany
🇵🇱
Szpital Specjalistyczny im. L.Rydygiera w Krakowie, Krakow, Poland

and more 40 locations

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Phase 2

Completed

Conditions: Immunoglobulin A (IgA) Nephropathy

Interventions: Other: Placebo
Drug: Felzartamab

First Posted Date: 2021-10-04

Last Posted Date: 2025-02-07

Lead Sponsor: HI-Bio, A Biogen Company

Target Recruit Count: 54

Registration Number: NCT05065970

Locations: 🇩🇪
Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany
🇨🇿
Fakultni nemocnice Kralovske Vinohrady Hospital, Prague, Praha, Hlavní Mesto, Czechia
🇬🇪
JSC Evex Hospitals, Tbilisi, Georgia

and more 57 locations